Picture EBD Group Bio-Europe Spring 2024 Barcelona 650x100px
Document › Details

BioPharmaSpec Ltd.. (2/27/18). "Press Release: BioPharmaSpec Launches New Host Cell Protein Detection Service". Malvern, PA & Jersey.

Organisations Organisation BioPharmaSpec Ltd.
  Group BioPharmaSpec (Group)
  Organisation 2 BioPharmaSpec Inc.
  Group BioPharmaSpec (Group)
Products Product mass spectrometry-based analysis of biopharmaceutical
  Product 2 proteomic services
Persons Person Reason, Andrew (BioPharmaSpec 201802 CEO)
  Person 2 Farrell, Lindsay (BioPharmaSpec 201802 Head of Business Development)

A Mass Spectrometry (MS) based approach in response to recent regulatory guidance

BioPharmaSpec, a leading contract research organization (CRO) providing a full range of characterization services for the biotechnology industry, today announced the launch of “The BioPharmaSpec Approach” for MS-based detection of Host Cell Proteins (HCPs). The new in-house service allows Clients access to a pre-existing approach that detects a wider population of HCPs than possible with traditional ELISA technologies.

In contrast to HCP-ELISA, which relies on the presence of polyclonal antibodies for positive HCP detection, The BioPharmaSpec Approach has the distinct advantage of detecting HCPs in a de novo manner, without specialized polyclonal antibody reagents or product / process-specific method development. BioPharmaSpec apply their renowned MS expertise within a clearly-defined, staged approach, which includes:

> Qualitative analysis to identify the HCPs present
> Quantitation against a response from a known spiked protein
> Quantitation of the HCPs against heavy labeled marker peptides

The application of this in-house service was discussed briefly ahead of the formal launch by BioPharmaSpec’s Technical Director for Structural Analysis, Dr. Richard Easton, during a live webinar entitled: “Characterizing Protein Impurities”. The webinar featured case studies of characterizing process related impurities, with an emphasis on Host Cell Proteins. Scientists can watch this webinar on-demand, by clicking here:

Dr Andrew Reason, CEO at BioPharmaSpec commented: “Through our significant experience, high-end MS technologies and intuitive, specialized software, our clients have been progressively adopting MS as technique for analyzing HCPs in their products. In turn, this trend has swayed regulatory groups worldwide, who now often recommend the use of MS as an orthogonal approach to HCP-ELISA.”

Dr. Reason continued, “At BioPharmaSpec, we remain committed to positioning ourselves at the forefront of our industry, constantly looking for ways to innovate and bring the best technical service to our Clients. We look forward to serving our industry with The BioPharmaSpec Approach to HCP detection, and improving HCP assessments with the more decisive analytical technique of MS.”

About BioPharmaSpec

BioPharmaSpec is a CRO specializing in the structural, physicochemical and biophysical characterization of biopharmaceuticals including monoclonal antibodies and their related products (e.g. biosimilars and biobetters, Antibody Drug Conjugates (ADCs), bispecifics and fusion proteins). We assist our clients in a range of analytical areas such as De Novo Protein Sequencing, Peptide Mapping, Disulfide Bridge Assignment, Carbohydrate Analysis and higher order structure assessment. Our analytical data can be used to choose the best cell clone, provide comparability studies and allow solid development decisions to be made based on quality analytical data and experience.


Lindsay Farrell
Head of Business Development
+44 (0)1534 483 493

Record changed: 2023-06-05


Picture Bionter Seeing Things witzh EVE the Particle Counter 650x200px

More documents for BioPharmaSpec (Group)

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to and simply fill the subject line with the word »MSC Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at and


Picture EBD Group Asia Bio Partnering Forum 2024 Singapore 650x300px

» top